Use of a Modified Adaptor Molecule LAT to Improve Immunotherapy for Cancer and Other Diseases


One problem with the development of immunotherapy for cancer or other diseases is the inability to stimulate a sufficient immune response in patients to tumor associated antigens. The Linker Adapted for T Cell Signaling molecule (LAT) has been shown to be an important molecule in T cell signaling. The inventions described and claimed in this patent application illustrate a new supportive role for LAT which may be harnessed to improve a patient's immune response to tumor-associated antigens.

A number of approaches to improving the immune response in cancer immunotherapy have been investigated. One such approach is to be able to influence the potency of T Cell Signaling. This invention exploits the role of LAT in T Cell signaling and provides a means to create a more intense and effective T Cell response. This would have the end result of improving the overall response of a patient's immune system to the presence of tumor-associated antigens.

With T Cell signaling being important in the body's immune response to bacterial and viral antigens it may also be possible to harness the modified LAT molecules to improve the immune response in developing immunotherapy for infectious disease.

Potential Commercial Applications: Competitive Advantages:
  • As an adjuvant with immunotherapeutic agents to improve the overall response of a patient's immune system to tumor associated antigens.
  • As an adjuvant with immunotherapeutic agents to improve the overall response of a patient's immune system to bacterial associated antigens.
  • As an adjuvant with immunotherapeutic agents to improve the overall response of a patient's immune system to viral associated antigens.
 
  • Enhanced T Cell Signaling should improve the overall effectiveness of immunotherapy producing a more robust patient response.


Development Stage:
Early-stage

Related Invention(s):
E-010-1998/1


Inventors:

Lawrence Samelson (NICHD)  ➽ more inventions...

Lakeshmi Balagopalan (NCI)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 8,779,095 issued 2014-07-15
U.S. Pat: 9,649,339 issued 2017-05-16
US Application No. 61/176,231
PCT Application No. PCT/US2010/033186

Collaboration Opportunity:

Researchers at the NCI seek licensing and/or co-development research collaborations for this technology using LAT signaling to improve immune response.


Licensing Contact:
Susan Rucker, J.D.
Email: susan.rucker@nih.gov
Phone: 240-276-6727

OTT Reference No: E-159-2009/0
Updated: Oct 23, 2017